

August 28, 2009

**Completion of the tender offer for acquisition of shares of
Noven Pharmaceuticals, Inc. by our subsidiary**

Hisamitsu Pharmaceutical Co., Ltd. (head office: Tosu City, Saga Prefecture, Japan; hereinafter the “Company”) announces that the Subsequent Offering Period set forth for the shareholders of Noven Pharmaceuticals, Inc. (head office: Miami, Florida, USA; hereinafter “Noven”) that has not tendered its shares before the end of the period of the tender offer for acquisition of shares of Noven instituted by Northstar Merger Sub, Inc. (head office: Delaware USA; hereinafter, “Northstar Merger”), a wholly owned subsidiary of Hisamitsu U.S., Inc. (head office: Delaware USA; hereinafter, “Hisamitsu U.S.”), a wholly owned subsidiary of the Company (hereinafter, the “Tender Offer”), ended on August 26 (Eastern Standard Time).

The results of the tender offer are as follows. As of 24:00, August 26, 2009 (Eastern Standard Time), combined with the shares tendered in the initial Tender Offer period (July 23, 2009 to August 19, 2009, Eastern Standard Time), a total of 22,320,889 shares of Noven were tendered, representing roughly 89.2% of Noven’s outstanding shares.

Northstar Merger further obtained 90% or more of Noven’s outstanding shares by exercising the option for acquiring new shares issued by Noven. With this achieved, on August 27, 2009 (Eastern Standard Time), pursuant to the laws of the State of Delaware, the Company carried out a short-form merger (a merger procedure not requiring a general shareholders meeting) between Noven and Northstar Merger, and on such day completed the approximately \$413 million cash acquisition of Noven. As of August 27, 2009, shares of Noven that were not tendered in the Tender Offer were converted into the right to receive cash in the amount of \$16.50 per share, the per-share purchase price in the Tender Offer, and Noven became a wholly owned subsidiary of Hisamitsu U.S.

The trading of Noven shares on the NASDAQ stock market will be suspended.